Budd-Chiari syndrome secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Mazia Fatima (talk | contribs) No edit summary |
Mazia Fatima (talk | contribs) No edit summary |
||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
Secondary prevention strategies following Budd-Chiari syndrome include: anticoagulation should be initiated immediately in patients to prevent propagation of the clot, provided there are no contraindications.Effective management of esophageal varices.Patients with Budd-Chiari syndrome treated with balloon dilatation or stents require follow-up catheterizations and repeat dilatations or stent replacement.All patients should have routine surveillance for hepatocellular carcinoma (HCC). | [[Secondary prevention]] strategies following Budd-Chiari syndrome include: [[anticoagulation]] should be initiated immediately in patients to prevent propagation of the [[clot]], provided there are no [[contraindications]]. Effective management of [[esophageal varices]]. [[Patients]] with Budd-Chiari syndrome treated with balloon [[dilatation]] or [[stents]] require follow-up [[Catheterization|catheterizations]] and repeat dilatations or [[stent]] replacement. All [[patients]] should have routine surveillance for [[Hepatocellular carcinoma|hepatocellular carcinoma (HCC)]]. | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
Secondary prevention strategies following Budd-Chiari syndrome include: <ref name="pmid26494427">{{cite journal |vauthors=Goel RM, Johnston EL, Patel KV, Wong T |title=Budd-Chiari syndrome: investigation, treatment and outcomes |journal=Postgrad Med J |volume=91 |issue=1082 |pages=692–7 |year=2015 |pmid=26494427 |doi=10.1136/postgradmedj-2015-133402 |url=}}</ref><ref name="pmid23411869">{{cite journal |vauthors=Ren W, Qi X, Yang Z, Han G, Fan D |title=Prevalence and risk factors of hepatocellular carcinoma in Budd-Chiari syndrome: a systematic review |journal=Eur J Gastroenterol Hepatol |volume=25 |issue=7 |pages=830–41 |year=2013 |pmid=23411869 |doi=10.1097/MEG.0b013e32835eb8d4 |url=}}</ref> | [[Secondary prevention]] strategies following Budd-Chiari syndrome include: <ref name="pmid26494427">{{cite journal |vauthors=Goel RM, Johnston EL, Patel KV, Wong T |title=Budd-Chiari syndrome: investigation, treatment and outcomes |journal=Postgrad Med J |volume=91 |issue=1082 |pages=692–7 |year=2015 |pmid=26494427 |doi=10.1136/postgradmedj-2015-133402 |url=}}</ref><ref name="pmid23411869">{{cite journal |vauthors=Ren W, Qi X, Yang Z, Han G, Fan D |title=Prevalence and risk factors of hepatocellular carcinoma in Budd-Chiari syndrome: a systematic review |journal=Eur J Gastroenterol Hepatol |volume=25 |issue=7 |pages=830–41 |year=2013 |pmid=23411869 |doi=10.1097/MEG.0b013e32835eb8d4 |url=}}</ref> | ||
*Anticoagulation should be initiated immediately in patients to prevent propagation of the clot, provided there are no contraindications. | *[[Anticoagulation]] should be initiated immediately in patients to prevent propagation of the [[clot]], provided there are no [[contraindications]]. | ||
*Effective management of esophageal varices. | *Effective management of [[esophageal varices]]. | ||
*Patients with Budd-Chiari syndrome treated with balloon dilatation or stents require follow-up catheterizations and repeat dilatations or stent replacement. | *Patients with Budd-Chiari syndrome treated with balloon dilatation or [[stents]] require follow-up [[Catheterization|catheterizations]] and repeat dilatations or [[Stent|stent replacement]]. | ||
*All patients should have routine surveillance for hepatocellular carcinoma (HCC). | *All patients should have routine surveillance for [[Hepatocellular carcinoma|hepatocellular carcinoma (HCC).]] | ||
==References== | ==References== | ||
Revision as of 18:59, 14 November 2017
|
Budd-Chiari syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Budd-Chiari syndrome secondary prevention On the Web |
|
American Roentgen Ray Society Images of Budd-Chiari syndrome secondary prevention |
|
Risk calculators and risk factors for Budd-Chiari syndrome secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Secondary prevention strategies following Budd-Chiari syndrome include: anticoagulation should be initiated immediately in patients to prevent propagation of the clot, provided there are no contraindications. Effective management of esophageal varices. Patients with Budd-Chiari syndrome treated with balloon dilatation or stents require follow-up catheterizations and repeat dilatations or stent replacement. All patients should have routine surveillance for hepatocellular carcinoma (HCC).
Secondary Prevention
Secondary prevention strategies following Budd-Chiari syndrome include: [1][2]
- Anticoagulation should be initiated immediately in patients to prevent propagation of the clot, provided there are no contraindications.
- Effective management of esophageal varices.
- Patients with Budd-Chiari syndrome treated with balloon dilatation or stents require follow-up catheterizations and repeat dilatations or stent replacement.
- All patients should have routine surveillance for hepatocellular carcinoma (HCC).
References
- ↑ Goel RM, Johnston EL, Patel KV, Wong T (2015). "Budd-Chiari syndrome: investigation, treatment and outcomes". Postgrad Med J. 91 (1082): 692–7. doi:10.1136/postgradmedj-2015-133402. PMID 26494427.
- ↑ Ren W, Qi X, Yang Z, Han G, Fan D (2013). "Prevalence and risk factors of hepatocellular carcinoma in Budd-Chiari syndrome: a systematic review". Eur J Gastroenterol Hepatol. 25 (7): 830–41. doi:10.1097/MEG.0b013e32835eb8d4. PMID 23411869.